CDSCO & PvPI: India’s Regulatory Framework in Depth

Everything else in this module has covered ICH, WHO, CIOMS, and EU frameworks — the frameworks a global case processor needs regardless of location. This lesson goes one level deeper into India’s own domestic system, because so much of the global PV workforce is physically based there, supporting sponsors and CROs worldwide, and interviewers at India-based employers routinely test this specifically.

CDSCO is India’s national regulatory authority for drugs, cosmetics, and medical devices, operating under the Drugs and Cosmetics Act. It oversees pharmacovigilance activity through PvPI, coordinates with the Indian Pharmacopoeia Commission, and conducts PV inspections directly. PvPI itself is the operational programme: it began in July 2010 with AIIMS New Delhi as the initial National Coordination Centre, and that coordination role shifted to the Indian Pharmacopoeia Commission (IPC) in Ghaziabad on April 15, 2011 — where it has remained since.

The programme runs through a network of ADR Monitoring Centres (AMCs) — hospitals and institutions that actually collect adverse event reports from clinicians and patients on the ground. That network has grown substantially: from a handful of centres at launch to 1,120 AMCs as of October 2025. Each AMC enters cases into Vigiflow, the case-management system PvPI uses, which then forwards them onward — first to PvPI/IPC nationally, and from there into WHO’s global VigiBase database through WHO-UMC, making India’s domestic reporting part of the same global signal-detection pool covered in Module 7.

For a case processor or associate working on India-facing PV activity, this matters operationally in a few concrete ways: CDSCO periodic safety reporting (PSUR/PMS submissions) follows its own timeline distinct from EMA’s PBRER cycle; Schedule Y governs clinical trial and post-marketing safety obligations specific to India; and an AMC-originated case may already carry a Vigiflow record before it ever reaches a CRO’s own safety database — which is exactly the kind of duplicate-detection scenario Module 10 covers from the database side.

Clinical trial SAEs run on a completely different, compensation-linked clock under the 2019 New Drugs and Clinical Trials Rules — worth knowing cold, since it’s distinct from the spontaneous post-marketing ADR flow described above. An investigator reports an SAE to the sponsor, the Ethics Committee, and CDSCO within 24 hours of first knowledge, then follows up with a full analyzed report within 14 days. If compensation is warranted, it moves through its own chain: the Ethics Committee recommends to the DCGI within 30 days, an Expert Committee reviews within a further 60, the DCGI issues its order within 90 days of receiving that report, and the sponsor pays out within 30 days of the order. Four separate clocks, each starting when the previous one ends — not one 14-day deadline covering the whole process.